As of 2026-02-26, the Relative Valuation of Avidity Biosciences Inc (RNA) is (86.29) USD. This relative valuation is based on P/E multiples. With the latest stock price at 72.80 USD, the upside of Avidity Biosciences Inc based on Relative Valuation is -218.5%.
The range of the Relative Valuation is (81.37) - (87.93) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.4x - 26.8x | 24.1x |
| Forward P/E multiples | 22.3x - 24.1x | 23.2x |
| Fair Price | (81.37) - (87.93) | (86.29) |
| Upside | -211.8% - -220.8% | -218.5% |
| Date | P/E |
| 2026-02-20 | -19.97 |
| 2026-02-19 | -19.97 |
| 2026-02-18 | -19.96 |
| 2026-02-17 | -19.97 |
| 2026-02-13 | -19.97 |
| 2026-02-12 | -19.98 |
| 2026-02-11 | -19.99 |
| 2026-02-10 | -19.98 |
| 2026-02-09 | -19.98 |
| 2026-02-06 | -19.98 |
| 2026-02-05 | -19.96 |
| 2026-02-04 | -19.93 |
| 2026-02-03 | -19.99 |
| 2026-02-02 | -19.94 |
| 2026-01-30 | -19.89 |
| 2026-01-29 | -19.89 |
| 2026-01-28 | -19.86 |
| 2026-01-27 | -19.91 |
| 2026-01-26 | -19.91 |
| 2026-01-23 | -19.90 |
| 2026-01-22 | -19.94 |
| 2026-01-21 | -19.91 |
| 2026-01-20 | -19.86 |
| 2026-01-16 | -19.87 |
| 2026-01-15 | -19.90 |
| 2026-01-14 | -19.88 |
| 2026-01-13 | -19.85 |
| 2026-01-12 | -19.83 |
| 2026-01-09 | -19.83 |
| 2026-01-08 | -19.83 |
| 2026-01-07 | -19.83 |
| 2026-01-06 | -19.80 |
| 2026-01-05 | -19.75 |
| 2026-01-02 | -19.76 |
| 2025-12-31 | -19.77 |
| 2025-12-30 | -19.77 |
| 2025-12-29 | -19.78 |
| 2025-12-26 | -19.77 |
| 2025-12-24 | -19.78 |
| 2025-12-23 | -19.77 |
| 2025-12-22 | -19.79 |
| 2025-12-19 | -19.83 |
| 2025-12-18 | -19.77 |
| 2025-12-17 | -19.70 |
| 2025-12-16 | -19.72 |
| 2025-12-15 | -19.69 |
| 2025-12-12 | -19.69 |
| 2025-12-11 | -19.62 |
| 2025-12-10 | -19.55 |
| 2025-12-09 | -19.54 |